Quick Answer
CANNAPHARMARX, INC. reported Total Revenue of $1.36 million for fiscal year 2025.
CANNAPHARMARX, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.36M +66.1% |
$820.1K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$11.13M -12.4% |
-$9.91M -368.6% |
$3.69M +143.2% |
-$8.53M +3.4% |
-$8.83M +55.6% |
-$19.89M +2.7% |
| Diluted EPS | -$0.02 +0.0% |
-$0.02 -300.0% |
$0.01 +125.0% |
-$0.04 -133.3% |
$0.12 | — |
| Total Assets | $7.02M -35.2% |
$10.84M -7.7% |
$11.75M +85.3% |
$6.34M +5442.8% |
$114.3K -98.7% |
$8.75M -45.4% |
| Cash and Equivalents | — | — | — | — | — | — |
| Stockholders Equity | -$30.15M -52.2% |
-$19.81M -63.0% |
-$12.15M -170.1% |
$17.34M +234.2% |
-$12.93M -46.9% |
-$8.80M -281.3% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$3.35M +7.8% |
-$3.63M -129.6% |
-$1.58M +69.7% |
-$5.21M -74.1% |
-$2.99M +79.3% |
-$14.49M +9.3% |
| Gross Profit | -$2.08M +29.0% |
-$2.93M | $0.00 | — | — | — |
| Shares Outstanding | 662.50M +0.0% |
662.50M +50.3% |
440.75M +60.8% |
274.12M +118.4% |
125.51M +167.1% |
46.99M +28.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $656.6K | +110.3% | +183.5% |
| Net Income | September 30, 2025 | -$1.48M | -884.3% | -4.6% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $11.62M | -0.6% | +1.3% |
| Cash and Equivalents | September 30, 2018 | $682.1K | — | +2970.3% |
| Stockholders Equity | September 30, 2025 | -$22.52M | -35.8% | +0.3% |
| R&D Expense | September 30, 2015 | $145.8K | +7.9% | -9.8% |
| Operating Income | September 30, 2025 | -$935.6K | -81.3% | -11.3% |
| Gross Profit | September 30, 2025 | -$440.0K | -23.5% | +29.2% |
| Shares Outstanding | September 30, 2025 | 662.50M | +0.0% | +0.0% |
- CANNAPHARMARX, INC. reported Total Revenue of $1.36 million for fiscal year 2025.
- CANNAPHARMARX, INC. showed an increase of +66.1% in Total Revenue compared to the prior fiscal year.
- CANNAPHARMARX, INC. reported Net Income of -$11.13 million for fiscal year 2025.
- CANNAPHARMARX, INC. showed a decrease of -12.4% in Net Income compared to the prior fiscal year.
- CANNAPHARMARX, INC. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2025.
- CANNAPHARMARX, INC. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- CANNAPHARMARX, INC. reported Total Assets of $7.02 million for fiscal year 2025.
- CANNAPHARMARX, INC. showed a decrease of -35.2% in Total Assets compared to the prior fiscal year.
- CANNAPHARMARX, INC. reported Cash and Equivalents of $0.00 for fiscal year 2017.
- CANNAPHARMARX, INC. reported Stockholders Equity of -$30.15 million for fiscal year 2025.
- CANNAPHARMARX, INC. showed a decrease of -52.2% in Stockholders Equity compared to the prior fiscal year.
- CANNAPHARMARX, INC. reported R&D Expense of $324.1 thousand for fiscal year 2014.
- CANNAPHARMARX, INC. reported Operating Income of -$3.35 million for fiscal year 2025.
- CANNAPHARMARX, INC. showed an increase of +7.8% in Operating Income compared to the prior fiscal year.
- CANNAPHARMARX, INC. reported Gross Profit of -$2.08 million for fiscal year 2025.
- CANNAPHARMARX, INC. showed an increase of +29.0% in Gross Profit compared to the prior fiscal year.
- CANNAPHARMARX, INC. reported Shares Outstanding of 662.50 million shares for fiscal year 2025.
- CANNAPHARMARX, INC. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: